DK0548123T3 - Anti-inflammatorisk faktor, fremgangsmåde til isolering og anvendelse - Google Patents

Anti-inflammatorisk faktor, fremgangsmåde til isolering og anvendelse

Info

Publication number
DK0548123T3
DK0548123T3 DK91915601T DK91915601T DK0548123T3 DK 0548123 T3 DK0548123 T3 DK 0548123T3 DK 91915601 T DK91915601 T DK 91915601T DK 91915601 T DK91915601 T DK 91915601T DK 0548123 T3 DK0548123 T3 DK 0548123T3
Authority
DK
Denmark
Prior art keywords
factor
milk
animal
inflammatory factor
isolation
Prior art date
Application number
DK91915601T
Other languages
English (en)
Inventor
Lee R Beck
Original Assignee
Stolle Milk Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Milk Biologics Inc filed Critical Stolle Milk Biologics Inc
Application granted granted Critical
Publication of DK0548123T3 publication Critical patent/DK0548123T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK91915601T 1990-09-11 1991-06-12 Anti-inflammatorisk faktor, fremgangsmåde til isolering og anvendelse DK0548123T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/580,382 US5242691A (en) 1982-06-03 1990-09-11 Anti-inflammatory factor, method of isolation, and use
PCT/US1991/004174 WO1992004035A1 (en) 1990-09-11 1991-06-12 Anti-inflammatory factor, method of isolation, and use

Publications (1)

Publication Number Publication Date
DK0548123T3 true DK0548123T3 (da) 1999-02-15

Family

ID=24320860

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91915601T DK0548123T3 (da) 1990-09-11 1991-06-12 Anti-inflammatorisk faktor, fremgangsmåde til isolering og anvendelse

Country Status (13)

Country Link
US (1) US5242691A (da)
EP (1) EP0548123B1 (da)
JP (1) JPH08502718A (da)
AT (1) ATE171875T1 (da)
AU (1) AU660626B2 (da)
CA (1) CA2090011C (da)
DE (1) DE69130323T2 (da)
DK (1) DK0548123T3 (da)
ES (1) ES2124229T3 (da)
IE (1) IE912109A1 (da)
IL (1) IL98647A (da)
NZ (2) NZ238751A (da)
WO (1) WO1992004035A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650175A (en) * 1982-06-03 1997-07-22 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5352462A (en) * 1982-06-03 1994-10-04 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
CA2086101C (en) * 1990-07-05 2002-11-19 Lee R. Beck Immune suppressive product from milk
US5747296A (en) * 1992-05-11 1998-05-05 Corvas International, Inc. Method of detecting neutophil inhibitory factor mimics
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
US5980953A (en) * 1994-10-03 1999-11-09 Stolle Milk Biologics, Inc. Anti-inflammatory factor, method of isolation, and use
DE19548221C1 (de) * 1995-12-22 1997-05-15 Biotest Pharma Gmbh Orale Anwendung von Immunglobulin-Präparationen zur Behandlung und Prophylaxe chronischer Schmerzzustände
CA2197515A1 (en) * 1996-07-15 1998-01-16 Reyad Mahmoud Methods of treating milk products
WO1998009717A1 (en) 1996-09-06 1998-03-12 Pall Corporation Shear separation method and system
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
JP2001342127A (ja) * 2000-06-02 2001-12-11 Nomoto Kikuo 腸吸収性抗炎症因子含有免疫性物質及びその応用
US20030099635A1 (en) * 2001-10-04 2003-05-29 Protein Therapeutics, Inc. Use of oral gammaglobulin for the treatment of immune-mediated diseases
US6770280B1 (en) 2001-11-15 2004-08-03 Humanetics Corporation Treatment of menorrhagia, hypermenorrhea, dysmenorrhea and menstrual migraines by the administration of an antibacterial milk product
US20080026983A1 (en) * 2006-07-28 2008-01-31 Gardiner Paul T Compositions and methods for alleviating joint pain and improving joint flexibility
JP2011051914A (ja) * 2009-08-31 2011-03-17 Obihiro Univ Of Agriculture & Veterinary Medicine 低温殺菌処理ホエータンパク濃縮物を含む腸管炎症抑制剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128230A (en) * 1961-04-04 1964-04-07 Sunbury Milk Products Co Milk having antibodies therein and process for producing same
US3376198A (en) * 1965-07-21 1968-04-02 Collins Products Inc Method of producing antibodies in milk
GB1211876A (en) * 1967-11-23 1970-11-11 Twyford Lab Ltd Improvements in and relating to prophylactic and therapeutic preparations
CH590064A5 (da) * 1973-11-28 1977-07-29 Biokema Sa
US4324782A (en) * 1974-01-28 1982-04-13 Beck Lee R Dental caries inhibiting product of immunized cow's milk having antibodies specific to killed Streptococcus mutans cells
US4732757A (en) * 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
DE3172807D1 (en) * 1981-04-28 1985-12-12 Stolle Res & Dev Method of obtaining an anti-inflammatory bovine milk
US4897265A (en) * 1983-10-27 1990-01-30 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US4956349A (en) * 1983-10-27 1990-09-11 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US4636384A (en) * 1982-06-03 1987-01-13 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
EP0300102B1 (en) * 1987-07-21 1993-03-24 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization

Also Published As

Publication number Publication date
WO1992004035A1 (en) 1992-03-19
IL98647A0 (en) 1992-07-15
EP0548123A1 (en) 1993-06-30
NZ238751A (en) 1994-03-25
CA2090011C (en) 2003-12-30
AU660626B2 (en) 1995-07-06
EP0548123A4 (en) 1993-12-08
NZ250386A (en) 1997-06-24
EP0548123B1 (en) 1998-10-07
AU8434091A (en) 1992-03-30
JPH08502718A (ja) 1996-03-26
ATE171875T1 (de) 1998-10-15
DE69130323D1 (de) 1998-11-12
IE912109A1 (en) 1992-03-11
ES2124229T3 (es) 1999-02-01
IL98647A (en) 1999-11-30
CA2090011A1 (en) 1992-03-12
US5242691A (en) 1993-09-07
DE69130323T2 (de) 1999-05-20

Similar Documents

Publication Publication Date Title
DK0548123T3 (da) Anti-inflammatorisk faktor, fremgangsmåde til isolering og anvendelse
DE3775805D1 (de) Arzneimittel zur behandlung periodontaler erkrankungen.
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE69434773D1 (de) Vorrichtung zur schnellen thermischen Behandlung zur Herstellung von Halbleiterwafern
ATE191475T1 (de) Verfahren zur isolierung, reinigung und rekristallisation von lutein aus verseiften marigold oleoresin und diesen verwendungen
DK158723C (da) Analogifremgangsmaade til fremstilling af triphenylimidazol-2-yloxyalkansyrer og derivater deraf
FI904204A0 (fi) Foerfarande foer framstaellning av cykliska aminosyraderivat och mellanprodukter.
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
DE3873855D1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.
DK610389D0 (da) Antiinflammatorisk faktor, fremgangsmaade til isolation og anvendelse heraf
ATE141613T1 (de) Prozess zur darstellung von aspartam aus einem diketopiperazin sowie neue zwischenprodukte und derivate dafür
DE69600983D1 (de) Kapselpräparate zur Behandlung von Pflanzen
AT383123B (de) Verfahren zur herstellung von neuen (+)-catechin- alpha- monohydrat
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DK0495953T3 (da) 10-(1-Hydroxyethyl)-11-oxo-1-azatricyclo-(7.2.0.0.3.8)undec-2-en-carboxylsyreestere og fremgangsmåde til fremstilling deraf
ATE17007T1 (de) Neue o-alkyl-o-carbamoyl-glycero-phosphocholine und verfahren zu ihrer herstellung.
DK0594528T3 (da) Fremgangsmåde og anlæg til behandling af halve slagtekroppe
DE69419954T2 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
DE3762526D1 (de) Hochkonzentrierte saeurezusammensetzungen fuer die behandlung von wasser und die reinigung von anlagen.
DE69610045T2 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
DK0533610T3 (da) Anlæg og fremgangsmåde til at producere cyanursyre
DE69125969D1 (de) Arzneimittel zur Behandlung zentraler neuro-degenerativer Erkrankungen
DE59102006D1 (de) Verfahren zur Isolierung reiner Dinitrotoluole.